Join to View Full Profile
450 Brookline Ave# Dana-FarBoston, MA 02215
Phone+1 617-632-6094
Fax+1 617-632-3479
Dr. Lee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2017 - 2020
Johns Hopkins UniversityResidency, Internal Medicine, 2014 - 2017
University of Pittsburgh School of MedicineClass of 2014
Certifications & Licensure
MA State Medical License 2017 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- A phase I clinical trial of radiation therapy, durvalumab and tremelimumab in recurrent gynecologic cancer.Kelly J Fitzgerald, Panagiotis Konstantinopoulos, Ursula Matulonis, Joyce Liu, Neil Horowitz
Gynecologic Oncology. 2025-04-23 - Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer.Panagiotis A Konstantinopoulos, Mingyang Cai, Elizabeth K Lee, Carolyn Krasner, Susana M Campos
JCO Precision Oncology. 2025-04-01 - Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers.Elizabeth K Lee, David L Kolin, Ursula A Matulonis, Britt K Erickson
Gynecologic Oncology. 2025-04-01
Journal Articles
- POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure.Lee EK, Lindeman NI, Matulonis UA, Konstantinopoulos PA, Gynecologic Oncology Reports, 5/2019
Press Mentions
Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian CancerMarch 17th, 2025- Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical TrialSeptember 15th, 2024
- Comprehensive cancer research from Dana-Farber to lead ESMO Congress 2024September 11th, 2024
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
